Risks of Living Donor Liver Transplantation Using Small-For-Size Grafts

被引:9
|
作者
Miyagi, Shigehito [1 ]
Shono, Yoshihiro [1 ]
Tokodai, Kazuaki [1 ]
Nakanishi, Wataru [1 ]
Nishimura, Ryuichi [1 ]
Fujio, Atsushi [1 ]
Sasaki, Kengo [1 ]
Miyazaki, Yuki [1 ]
Kakizaki, Yuta [1 ]
Sasajima, Hideaki [1 ]
Kamei, Takashi [1 ]
Unno, Michiaki [1 ]
机构
[1] Tohoku Univ, Dept Surg, Grad Sch Med, Sendai, Miyagi, Japan
关键词
SPLENECTOMY;
D O I
10.1016/j.transproceed.2020.01.136
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. In living donor liver transplantation (LDLT), a graft-to-recipient weight ratio (GRWR) of under 0.8 is recognized as the critical graft size. Our aim was to compare the survival rates of recipients with small-for-size grafts (SFSG: GRWR <0.8), normal-sized grafts (NSG), and large-for-size grafts (LFSG: GRWR >= 3.5) and to investigate the mortality risk with SFSG. Methods. Between 1991 and April 2019, we performed 188 LDLT surgeries. Recently, we added splenectomy when portal vein pressure is high (>17 mm Hg) to interrupt the splenic bloodstream. We divided all LDLT cases retrospectively into 3 groups: an SFSG group (n = 22), NSG group (n = 154), and LFSG group (n = 12). We investigated the survival rates in these groups. Furthermore, we divided the SFSG group into 2 subgroups: an SFSG with splenectomy (SFSGthornS) group (n = 7) and an SFSG without splenectomy group. We investigated the occurrence rates of lethal complications such as portal vein thrombosis, hepatic artery thrombosis, and hepatic vein thrombosis. Results. The 5-year survival rate in the SFSG group was significantly lower (52.8%) than in the other groups (NSG: 84.5%; LFSG: 83.3%), but that of the SFSGthornS group was similar (80.0%) to that of other groups. There was no difference in the occurrence of postoperative complications such as portal vein thrombosis, hepatic artery thrombosis, or hepatic vein thrombosis between the SFSGthornS group and other groups. Conclusions. Graft survival of LDLT using SFSGthornS was as good as that of normal-sized grafts. Reducing portal vein pressure was important for SFSG.
引用
收藏
页码:1825 / 1828
页数:4
相关论文
共 50 条
  • [31] ABO-incompatible living donor liver transplantation is suitable in patients without ABO-matched donor
    Kim, Jong Man
    Kwon, Choon Hyuck David
    Joh, Jae-Won
    Kang, Eun-Suk
    Park, Jae Berm
    Lee, Joon Hyeok
    Kim, Sung Joo
    Paik, Seung Woon
    Lee, Suk-Koo
    Kim, Dae Won
    JOURNAL OF HEPATOLOGY, 2013, 59 (06) : 1215 - 1222
  • [32] Thrombopoietin levels and peripheral platelet counts following living related donor liver transplantation
    Tsukahara, A
    Sato, Y
    Yamamoto, S
    Suzuki, S
    Nakatsuka, H
    Watanabe, T
    Kameyama, H
    Hatakeyama, K
    HEPATO-GASTROENTEROLOGY, 2003, 50 (49) : 227 - 230
  • [33] Portal vein thrombosis in biliary atresia patients after living donor liver transplantation
    Ou, Hsin-You
    Concejero, Allan M.
    Huang, Tung-Liang
    Chen, Tai-Yi
    Tsang, Leo Leung-Chit
    Chen, Chao-Long
    Yu, Pao-Chu
    Yu, Chun-Yen
    Cheng, Yu-Fan
    SURGERY, 2011, 149 (01) : 40 - 47
  • [34] The role of apheresis therapy for ABO incompatible living donor liver transplantation: The Kyoto University experience
    Kozaki, Koichi
    Egawa, Hiroto
    Ueda, Mikiko
    Oike, Fumitaka
    Yoshizawa, Atsushi
    Fukatsu, Atsushi
    Takada, Yasutsugu
    THERAPEUTIC APHERESIS AND DIALYSIS, 2006, 10 (05) : 441 - 448
  • [35] ABO-Incompatible Adult Living Donor Liver Transplantation Under the Desensitization Protocol With Rituximab
    Song, G. -W.
    Lee, S. -G.
    Hwang, S.
    Kim, K. -H.
    Ahn, C. -S.
    Moon, D. -B.
    Ha, T. -Y.
    Jung, D. -H.
    Park, G. -C.
    Kim, W. -J.
    Sin, M. -H.
    Yoon, Y. -I.
    Kang, W. -H.
    Kim, S. -H.
    Tak, E. -Y.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2016, 16 (01) : 157 - 170
  • [36] Is Portal Venous Pressure Modulation Still Indicated for All Recipients in Living Donor Liver Transplantation?
    Yao, Siyuan
    Kaido, Toshimi
    Uozumi, Ryuji
    Yagi, Shintaro
    Miyachi, Yosuke
    Fukumitsu, Ken
    Anazawa, Takayuki
    Kamo, Naoko
    Taura, Kojiro
    Okajima, Hideaki
    Uemoto, Shinji
    LIVER TRANSPLANTATION, 2018, 24 (11) : 1578 - 1588
  • [37] Management of ABO-Incompatible Living-Donor Liver Transplantation: Past and Present Trends
    Raut, Vikram
    Uemoto, Shinji
    SURGERY TODAY, 2011, 41 (03) : 317 - 322
  • [38] Kinetics of B, T, NK lymphocytes and isoagglutinin titers in ABO incompatible living donor liver transplantation using rituximab and basiliximab
    Lee, Seung Duk
    Kim, Seong Hoon
    Kong, Sun-Young
    Kim, Young-Kyu
    Park, Sang-Jae
    TRANSPLANT IMMUNOLOGY, 2015, 32 (01) : 29 - 34
  • [39] Hepatic Arterial Buffer Response after Pediatric Living Donor Liver Transplantation: Report of a Case
    Sanada, Y.
    Mizuta, K.
    Urahashi, T.
    Ihara, Y.
    Wakiya, T.
    Okada, N.
    Yamada, N.
    Egami, S.
    Hishikawa, S.
    Ushijima, K.
    Otomo, S.
    Sakamoto, K.
    Yasuda, Y.
    Kawarasaki, H.
    TRANSPLANTATION PROCEEDINGS, 2011, 43 (10) : 4019 - 4024
  • [40] Left Lobe First With Purely Laparoscopic Approach A Novel Strategy to Maximize Donor Safety in Adult Living Donor Liver Transplantation
    Fujiki, Masato
    Pita, Alejandro
    Kusakabe, Jiro
    Sasaki, Kazunari
    You, Taesuk
    Tuul, Munkhbold
    Aucejo, Federico N.
    Quintini, Cristiano
    Eghtesad, Bijan
    Pinna, Antonio
    Miller, Charles
    Hashimoto, Koji
    Kwon, Choon Hyuck David
    ANNALS OF SURGERY, 2023, 278 (04) : 479 - 488